IP Library Granted Patent US 10,130,580
Granted Patent B2
US 10,130,580 · App. 15/958,512 · Granted Nov 20, 2018

Taste-masked pharmaceutical compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,130,580
App. No.
15/958,512
Granted
Nov 20, 2018
Kind
B2
Abstract

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short T max ). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

Claims (17)

1. A pharmaceutical composition comprising:

(1) a plurality of taste-masked particles, wherein each taste-masked particle comprises:

(a) a drug-containing core particle;

(b) a taste-masking membrane disposed on said drug-containing core particle comprising a combination of a water-insoluble polymer and a gastrosoluble polymer, wherein the water-insoluble polymer is ethylcellulose and the gastrosoluble polymer is an aminoalkyl methacrylate copolymer; wherein the weight ratio of the water-insoluble polymer to the gastrosoluble polymer in the taste-masking membrane is about 50/50, and the taste-masking membrane thickness ranges from about 10% to 30% by weight of the coated particle,

and the pharmaceutical composition releases greater than or equal to about 60% of the total amount of drug in 30 minutes when tested for dissolution using United States Pharmacopoeia Apparatus 2 using paddles at 50 rpm in 900 mL of 0.1 N HCl at pH 1.2; and

(2) a plurality of rapidly-dispersing microgranules having an average particle size of not more than about 400 μm comprising (i) a disintegrant and (ii) a sugar alcohol or a saccharide or a combination thereof, wherein each of said disintegrant and sugar alcohol or saccharide is present in the form of particles having an average particle diameter of not more than about 30 μm, and wherein the pharmaceutical composition is an orally disintegrating tablet.

2. The pharmaceutical composition of claim 1 comprising one or more drug(s) present in sufficient quantities to be administered orally to a patient in need thereof at a prescribed dosing regimen to provide therapeutic efficacy.

3. The pharmaceutical composition of claim 1 wherein the sugar alcohol or saccharide to disintegrant weight ratio is about 95/5.

4. The pharmaceutical composition of claim 1 , wherein the ratio of rapidly-dispersing microgranules to taste-masked particles ranges from about 2/1.

5. The pharmaceutical composition of claim 1 , wherein the rapidly-dispersing microgranules comprise a disintegrant selected from the group consisting of crosslinked polyvinylpyrrolidone, sodium starch glycolate, crosslinked sodium carboxymethylcellulose, low-substituted hydroxypropylcellulose and mixtures thereof.

6. The pharmaceutical composition of claim 1 , wherein the rapidly-dispersing microgranules comprise (i) the disintegrant crosslinked polyvinylpyrrolidone and (ii) the sugar alcohol mannitol.

7. The pharmaceutical composition of claim 1 , wherein the average particle size of the drug-containing core particle is not more than about 400 μm.

8. The pharmaceutical composition of claim 1 , wherein said orally disintegrating tablet has a friability of not more than about 1%.

9. The pharmaceutical composition of claim 1 , wherein said orally disintegrating tablet disintegrates on contact with the saliva in the oral cavity within approximately 60 seconds.

10. The pharmaceutical composition of claim 1 , wherein the rapidly dispersing microgranules comprise a sugar alcohol or a saccharide selected from the group consisting of mannitol.

11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition exhibits acceptable taste-masking when placed in the oral cavity for 60 seconds.

12. The pharmaceutical composition of claim 1 , wherein the rapidly dispersing microgranules have an average particle size of not more than 300 μm.

Assignments (5)
SECURITY INTEREST Recorded Nov 8, 2022
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: TEAL MIDCO HOLDINGS, L.P.
Reel/Frame 061698/0541 →
SECURITY INTEREST Recorded Sep 22, 2020
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: CRESCENT AGENCY SERVICES LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 053849/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: VENKATESH, GOPI M
To: EURAND, INC.
Reel/Frame 045756/0042 →
CHANGE OF NAME Recorded May 9, 2018
From: EURAND, INCORPORATED
To: APTALIS PHARMATECH, INC.
Reel/Frame 046115/0610 →
CHANGE OF NAME Recorded May 9, 2018
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 046115/0613 →